clinical trial · NCT07207811
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S·phase3·recruiting·n = 1,280
Transthyretin Amyloid Cardiomyopathy (ATTR CM)NNC6019-0001Placebo (NNC6019-0001)
brief summary
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
started
Oct 2, 2025
primary completion
Jun 29, 2029
completion
Jun 29, 2029
last updated
Apr 27, 2026
official title
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol